Vincenzo Silani
University of Milan
466 Papers
1.3K Citations
Vincenzo Silani is an academic researcher from University of Milan. The author has contributed to research in topics: Medicine & Amyotrophic lateral sclerosis. The author has an hindex of 69, co-authored 368 publications. Previous affiliations of Vincenzo Silani include Mayo Clinic & University of Massachusetts Medical School.
Chat about Author
Papers
Scientific and clinic highlights from the 15th International Symposium on MND.
TL;DR: Treatment of SOD1G93A mice at the early presymptomatic stage with pentoxifylline or revimide, two pharmacological agents which inhibit TNFa by destabilizing its RNA, significantly delayed disease progression and death and reduced motor neuron loss.
1
APS and the Nervous System
Cecilia Beatrice Chighizola,Davide Sangalli,Barbara Corra,Vincenzo Silani,L. Adobbati +4 more
- 01 Jan 2015
TL;DR: The wide heterogeneity in neurological presentation of APS represents a challenge for clinicians: it is important to promptly recognize and effectively treat them in early stages, in order to avoid diagnostic and therapeutic delay.
1
Mutations in the tail domain of the neurofilament heavy chain gene increase the risk of amyotrophic lateral sclerosis
H. Marriott,T. Spargo,Ahmad Al Khleifat,Isabella Fogh,Project Mine ALS sequencing consortium,P. M. Andersen,Nazli Basak,Johnathan Cooper-Knock,Philippe Corcia,P. Couratier,M. de Carvalho,Vivian E. Drory,Jonathan D. Glass,Marc Gotkine,Orla Hardiman,John Landers,Russell L. McLaughlin,Jesus S. Mora Pardina,Karen E. Morrison,S. Pinto,Mònica Povedano,L. E. Shaw,Pamela J. Shaw,Vincenzo Silani,Nicola Ticozzi,Philip Van Damme,Leonard H. van den Berg,Patrick Vourc'h,M. Wéber,Jan H. Veldink,Ruth Dobson,Pascale Schwab,Ammar Al-Chalabi,Alfredo Iacoangeli +33 more
TL;DR: In this paper , a fixed and random effects model meta-analysis of published case-control studies reporting NEFH variant frequencies using next-generation sequencing, microarray or PCR-based approaches was performed.
Clinimetrics and feasibility of the Italian version of the Frontal Assessment Battery (FAB) in non-demented Parkinson’s disease patients
E Aiello,Alfonsina D'Iorio,Federica Solca,Silvia Torre,Ruggero Bonetti,Francesco Scheveger,Eleonora Colombo,Alessio Maranzano,Luca Maderna,Claudia Morelli,Alberto Doretti,Marianna Amboni,Carmine Vitale,Federico Verde,Roberta Ferrucci,Sergio Barbieri,E Zirone,Alberto Priori,Gabriella Pravettoni,Gabriella Santangelo,Vincenzo Silani,Nicola Ticozzi,Andrea Ciammola,Barbara Poletti +23 more
TL;DR: The FAB predicted MoCA scores at both T0 and T1, converged with the vast majority of second-level cognitive measures and was associated with functional independence and apathy.
1